Redefining Noninvasive
Ocular Therapeutics
Publications and Presentations on Aciont's Research
Recent Publications
An ongoing series of informational entries
December 6, 2018
Ophthalmology researchers discuss the first in human phase 1/2 clinical study and data of DSP-Visulex.
April 15, 2020
Ophthalmology researchers led by Molokhia et. al discuss various animal models (PK and efficacy) demonstrating the delivery of macromolecules using process known as electroosmosis.
Other Recent Publications
An ongoing series of informational entries
David Miller and Kevin Li and colleagues discuss the effects of intraocular clearance using a topical ocular drug delivery system.
November, 2017
Papangkorn and colleagues discuss efficacy in a pan uveitis (ocular inflammation induction) model in rabbit with respect to a wide variety of treatment modalities (treatment time duration and concentration/formulation) with DSP-Visulex.
February, 2018
Papangkorn and colleagues discuss drug transport kinetics and safety with respect to a wide variety of treatment modalities (treatment time duration and concentration/formulation) with DSP-Visulex.
Archived Research Presentations
An ongoing series of informational entries
By John Higuchi; Kongnara Papangkorn; Sarah Molokhia; Donald Mix; Charlotte Butler; Prasoona Karra; Balbir Brar; S. Kevin Li; William I. Higuchi
David Miller and Kevin Li and colleagues discuss the effects of intraocular clearance using a topical ocular drug delivery system.
By Sarah A. Molokhia; Kongnara Papangkorn; Donald Mix; Charlotte Butler; Prasoona Karra; John Higuchi; Balbir Brar; S. Kevin Li; William I. Higuchi
By Sarah Molokhia; Kongnara Papangkorn; Charlotte Butler; Michael Burr; John Higuchi; Balbir Brar; Balamurali Ambati; William Higuchi
Research Presentations
An ongoing series of informational entries
By J. W. Higuchi; W. I. Higuchi; K. Papangkorn; S. K. Li; R. P. Kochambilli; A. L. Tuitupou; D. C. Mix, Jr.
Papangkorn and colleagues discuss efficacy in a pan uveitis (ocular inflammation induction) model in rabbit with respect to a wide variety of treatment modalities (treatment time duration and concentration/formulation) with DSP-Visulex.
By K. Papangkorn; D. C. Mix, Jr.; K. M. Gupta; J. W. Higuchi; B. Brar; S. K. Li; W. I. Higuchi
Papangkorn and colleagues discuss drug transport kinetics and safety with respect to a wide variety of treatment modalities (treatment time duration and concentration/formulation) with DSP-Visulex.